Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $57.48, for a total value of $9,556,050.00. Following the completion of the transaction, the chief executive officer owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 6.3%

TEM stock traded up $3.67 during mid-day trading on Wednesday, hitting $61.60. 8,936,767 shares of the company were exchanged, compared to its average volume of 6,015,111. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The firm’s 50 day simple moving average is $50.19 and its 200 day simple moving average is $54.68. The firm has a market cap of $11.06 billion, a P/E ratio of -35.81 and a beta of 3.62.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s revenue was up 36.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.24) EPS. On average, sell-side analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on TEM. BTIG Research restated a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Monday, June 1st. TD Cowen increased their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Guggenheim decreased their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Finally, Morgan Stanley lowered their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.54.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI during the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI during the third quarter worth $38,000. Whittier Trust Co. raised its position in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares in the last quarter. Finally, Lodestone Wealth Management LLC acquired a new stake in Tempus AI in the fourth quarter valued at $42,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.